Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
1. A method of treating diabetes mellitus, comprising:
administering to a subject in need thereof a therapeutically effective amount of a urolithin or a salt thereof.
2. The method of claim 1 , wherein the urolithin is urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof.
3. The method of claim 2 , wherein the urolithin is urolithin A.
4. The method of claim 2 , wherein the urolithin is urolithin B.
5. The method of claim 1 , wherein the subject is a mammal.
6. The method of claim 5 , wherein the mammal is a human.
7. The method of claim 1 , wherein the urolithin is administered orally.
8. The method of claim 1 , wherein the urolithin is administered topically.
9. The method of claim 1 , wherein the urolithin is administered parenterally.
10. The method of claim 1 , wherein the urolithin is administered as a food product, food additive, food ingredient, functional food, medical food, dietary supplement, nutraceutical, nutritional supplement or oral preparation.
11. The method of claim 1 , wherein the urolithin is administered as a pharmaceutical composition.
12. The method of claim 3 , wherein the subject is a mammal.
13. The method of claim 12 , wherein the mammal is a human.
14. The method of claim 13 , wherein the urolithin is administered orally.
15. The method of claim 13 , wherein the urolithin is administered topically.
16. The method of claim 13 , wherein the urolithin is administered parenterally.
17. The method of claim 13 , wherein the urolithin is administered as a food product, food additive, food ingredient, functional food, medical food, dietary supplement, nutraceutical, nutritional supplement or oral preparation.
18. The method of claim 13 , wherein the urolithin is administered as a pharmaceutical composition.